Background Although hormone replacement therapy has been associated with reduction of cardiovascular events in postmenopausal women, the mechanisms that mediate this apparent benefit are unclear. Because improvement in vasomotor function may represent one of the beneficial effects of estrogen administration, we investigated the acute effects of physiological levels of estrogen on the vascular responses of estrogen-deficient postmenopausal women.
Methods and Results The study included 40 postmenopausal women 60±8 years old (mean±SD), 20 of whom had one or more conditions associated with vascular dysfunction (hypertension, hypercholesterolemia, diabetes, or coronary artery disease). The forearm vascular responses to the endothelium-dependent vasodilator acetylcholine were studied before and during infusion of 17f3-estradiol into the ipsilateral brachial artery. In 31 subjects, the effect of estradiol on the responses to the endothelium-independent vasodilator sodium nitroprusside was also studied. Women with risk factors for vascular dysfunction had significantly reduced vasodilator responses to acetylcholine (P=.01) and to sodium nitroprusside (P<.001) compared with healthy subjects. Intra-arterial infuTNhe observation that the incidence of cardiovascular events in women increases after menopause has led to the hypothesis that estrogen deficiency may play a role in cardiovascular disease.' Indeed, epidemiological studies have shown that estrogen replacement is associated with an approximately 50% reduction in the incidence of coronary events in postmenopausal women. 23 However, the mechanisms underlying this apparent beneficial effect of estrogen replacement therapy are not fully understood. Although one mechanism may be a favorable effect of estrogen on the lipid profile,4,5 lipid changes appear to be insufficient to explain the magnitude of the observed reduction in cardiac events.' Therefore, the The endothelium has a critical role in the control of blood flow and the interaction between the blood and the vessel wall. Increasingly, endothelial dysfunction is recognized as an important factor in the development and manifestations of vascular disease.14'15 Impaired endothelium-dependent vasodilation has been demonstrated in patients with atherosclerosis16'7 and in conditions predisposing to the development of atherosclerosis, such as hypertension, '8,19 hypercholesterolemia,20,21 and diabetes.22 24Thus, a beneficial effect of estrogen on endothelial function could be a mechanism by which cardiovascular disease events are reduced. Therefore, we undertook the present study to investigate the effects of acute estrogen administration on endothelium-dependent and -independent vasodilation in postmenopausal women.
Methods Study Population months. Six women were receiving appropriate thyroid replacement therapy. Twenty women, 59±8 years old (range, 47 to 73 years), had no evidence of cardiovascular disease, present or past hypertension, diabetes mellitus, or hypercholesterolemia. The other 20 women, 61±8 years old (range, 45 to 72 years), had one or more conditions known to be associated with impaired endothelium-mediated vasodilation; 6 (30%) had coronary artery disease, 13 (65%) had a history of hypertension, 9 (45%) had total cholesterol >250 mg/dL, and 5 (25%) had diabetes mellitus, with 2 or more of these conditions present in 7 women (35%). Women were excluded from study if they had unstable angina, cardiac failure, severe hypertension (>180/110 mm Hg) off medication, untreated hypothyroidism, or any other major systemic illness. The study was approved by the National Heart, Lung, and Blood Institute Review Board, and all subjects gave written informed consent.
Protocol
Studies were performed in the morning, in a quiet room, with the temperature maintained at approximately 22°C (72°F). Subjects were asked to refrain from drinking alcohol or beverages containing caffeine and from smoking for at least 24 hours before the study. All medications except for diabetic medication and thyroid replacement therapy were stopped for at least 5 half-lives before each study. Aspirin and other nonsteroidal anti-inflammatory drugs were stopped at least 10 days before study. Subjects came to the laboratory after a light breakfast.
While the subjects were supine, a cannula (13/4 in, 20 gauge, Arrow) was inserted into the brachial artery of the nondominant arm. A second cannula (1 in, 20 gauge, Jelco) was inserted into a deep antecubital vein of the same arm in 31 subjects. The arm was slightly elevated above the level of the right atrium, and a mercury-filled Silastic strain gauge was placed around the widest part of the forearm. The strain gauge was connected to a plethysmograph (model EC4, DE Hokanson) calibrated to measure the percent change in volume. 25 The plethysmograph, in turn, was connected to a chart recorder (Pharmacia LKB, Biotechnology).
For each measurement, a cuff placed on the upper arm was inflated to 40mm Hg with a rapid cuff inflator (model E10, DE Hokanson) to occlude venous outflow from the extremity, and a wrist cuff was inflated to 50 mm Hg above systolic pressure 1 minute before each measurement to exclude the hand circulation. Flow measurements were recorded every 15 seconds for a period of approximately 7 seconds. Seven readings were obtained for each mean value at rest and during drug infusions. Forearm blood flow was expressed as milliliters per minute per 100 mL of forearm volume. Brachial artery pressure was measured directly from the intra-arterial catheter with a Spacelabs monitor (model 90308). Forearm vascular resistance was calculated as the mean arterial pressure divided by the forearm blood flow and is expressed as units.
An intra-arterial infusion of 5% dextrose solution was begun at 1 mLlmin, with basal measurements obtained 3 minutes later. Forearm blood flow was then measured during the additional intra-arterial infusion of acetylcholine chloride (Sigma Chemical Co) at 7.5, 15, and 30 ,ug/min (n=40) and sodium nitroprusside at 0.8, 1.6, and 3.2 gg/min (n=31).
Infusion rates (0.25, 0.5, and 1 mL/min) were identical for both drugs. Each dose was infused for 5 minutes, and forearm blood flow was measured in the last 2 minutes of each infusion. The order of administration of acetylcholine and sodium nitroprusside was randomized, and a 30-minute rest period ensued between infusions.
Acute Estradiol Administration
After another 30-minute rest period, an intra-arterial infusion of 17,3-estradiol (United States Pharmacopeia) replaced the infusion of 5% dextrose. The aim of the infusion was to increase the ipsilateral forearm venous estradiol concentration to approximately 300 pg/mL, levels typical of reproductive-age women at midcycle.26 Estradiol 20 ng/mL was infused at 1 mL/min, an infusion concentration and rate we found to produce a steady-state concentration by 20 minutes of infusion. Accordingly, after 20 minutes of infusion, resting forearm blood flow measurements and an ipsilateral forearm venous blood sample for estradiol concentration, subsequently measured by radioimmunoassay (Diagnostic Products Corp), were obtained. Estradiol infusion was maintained at the same rate while acetylcholine and sodium nitroprusside dose-response curves were repeated in the same order in which they had been performed earlier.
To achieve solubility in 5% dextrose, 171-estradiol required dilution in 0.66% ethanol. To determine whether this concentration of ethanol could affect forearm vascular tone at rest or the response to acetylcholine, 0.66% ethanol alone was infused at 1 mL/min for 20 minutes before administration of estradiol, and a resting forearm blood flow measurement and acetylcholine dose-response curve were obtained during continued ethanol infusion in 16 subjects.
Statistical Analysis
Student's t test for paired data was used to compare resting measurements before and after estradiol and ethanol. The dose-response curves to acetylcholine and sodium nitroprusside obtained before and after interventions were compared by repeated-measures ANOVA allowing for interaction. Associations between the effects of estradiol and clinical parameters were assessed by linear regression analysis and calculation of a correlation coefficient. Data are expressed as mean ± Fig 3) . Although the forearm flow response of healthy women to sodium nitroprusside was potentiated by estradiol (Table 1) , this response was due to the higher mean blood pressure at this point of the study; the forearm vascular resistance during sodium nitroprusside was unaltered by estradiol (Fig 3) .
Vascular Effect of Ethanol Diluent
Infusion of the ethanol (0.66%) diluent alone in 16 women caused a 20+13% decrease in forearm blood flow (2.8±0.9 to 2.2±0.8 mL* min 1 100 mL-1, P<.001) and a 30±14% increase in forearm vascular resistance (39±13 to 50±18 U, P<.00l). The increase in resistance was similar for the 8 healthy women and the 8 women with risk factors for vascular disease (35±21% versus 29±23% increase from baseline, P=.31). This effect was similar to the vasoconstriction observed after estradiol administration. However, ethanol had no effect on the vascular response to acetylcholine (Fig 4) . Discussion This study demonstrates that intra-arterial infusion of 17,B-estradiol, achieving serum concentrations typical of reproductive-age women at midcycle, selectively potentiates the endothelium-dependent vasodilator response to acetylcholine in healthy women. We also found that estradiol potentiates the vasodilator responses to acetylcholine and to sodium nitroprusside in the forearm of postmenopausal women with risk factors for atherosclerosis and evidence of impaired vascular responses to these same agonists. Because there was no evidence of a direct vasodilator effect of estradiol at baseline, the augmentation of acetylcholine-induced vasodilation probably reflects an actual potentiation of endothelium- The mechanism by which estradiol acutely enhances vascular function cannot be determined from the present study. The primary mechanism of action of estrogen and other steroid hormones involves receptor-mediated transport to the nucleus, with subsequent regulation of gene transcription and thereby of protein expression.32 However, the rapidity with which vasodilation was enhanced in this study (within 20 minutes) indicates that altered protein expression is unlikely to be the responsible mechanism and indirectly suggests that other estrogen effects must be operative. Preliminary data from our laboratory indicate that the effect of estradiol on the endothelium is mediated in part by enhanced release of nitric oxide.33 In our study, determination of the true effect of estradiol on resting forearm vascular tone was hampered by the mild vasoconstriction induced by the ethanol diluent. However, the occurrence of vasoconstriction with estradiol in ethanol diluent to the same degree as with ethanol alone suggests that estradiol did not have a significant, independent vasodilator effect in the forearm at the doses used in our study. The mild elevation in systemic blood pressure observed in the latter half of the study probably reflects the long study duration (4 to 5 hours) rather than an effect of the small doses of ethanol and estradiol used. However, because blood pressure changed, our analysis relied on the effect of estradiol on vascular resistance rather than flow alone.
A number of other questions arise from these results, such as whether the improvement of vascular function observed with acute, local estrogen administration is maintained during chronic estrogen replacement therapy. The acute vascular effect of 1713-estradiol in our study was achieved at physiological estradiol levels, typical of reproductive-age women in the middle of the menstrual cycle.26 However, postmenopausal hormone replacement therapy may achieve lower estrogen levels, and thus vascular effects may be less prominent. The estrogen preparation used in our study, 17fl-estradiol, is the most abundant and potent naturally occurring estrogen in reproductive-age women; whether other estrogen preparations, such as the more commonly used conjugated equine estrogens, have the same effect on endothelium-dependent vasodilation is unknown. Finally, it is possible that other vascular beds, such as the coronary circulation, respond differently to estrogen administration than the forearm vascular bed.
In conclusion, the acute intra-arterial infusion of 17/3-estradiol potentiates endothelium-dependent vasodilation in the forearm of postmenopausal women. This effect was observed both in women at increased risk for cardiovascular complications and in healthy women. Estradiol additionally potentiated endothelium-independent vasodilation in women with risk factors for and evidence of impaired vascular function. These vascular effects may be partly responsible for the long-term benefit of estrogen replacement therapy on cardiovascular events in postmenopausal women.
